Lupus Clinical Trial Tracker — Monitor the SLE and Lupus Nephritis Pipeline

Why lupus trial monitoring is essential in 2026

Systemic lupus erythematosus (SLE) affects roughly 1.5 million Americans, with lupus nephritis developing in 40–60% of patients and representing the leading cause of lupus-related morbidity and mortality. After decades with only hydroxychloroquine and belimumab as approved therapies, the SLE pipeline is now among the most active in all of immunology.

The clinical trial landscape for lupus in 2026 is characterized by rapid evolution across multiple mechanisms:

• Type I interferon pathway blockade — anifrolumab (AstraZeneca) approved in 2021; multiple follow-on programs targeting IFNAR, TYK2, and upstream sensors entering trials
• B cell depletion and tolerance — obinutuzumab, ianalumab (BAFF/IL-21), and CD19 CAR-T programs (BMS-986325 from 2seventy bio) now in Phase 2/3
• CAR-T in autoimmune disease — the paradigm shift of 2024–2025; multiple groups now studying CD19-targeted CAR-T for refractory SLE with remarkable early results
• Plasma cell targeting — daratumumab (anti-CD38), BCMA-targeted approaches moving into SLE/LN
• Calcineurin inhibitors and JAK inhibitors — voclosporin approved for LN; multiple JAK inhibitor programs (upadacitinib, deucravacitinib) in SLE trials
• Complement system — C3, C5, and factor D inhibitors being studied in LN

What we monitor for lupus

Our daily ClinicalTrials.gov pipeline can be configured for precise lupus trial tracking:

• Condition keywords: "systemic lupus erythematosus", "SLE", "lupus nephritis", "discoid lupus", "neuropsychiatric lupus", "NPSLE"
• Mechanism keywords: "IFNAR", "type I interferon", "CD19 CAR-T", "BAFF", "belimumab combination", "TYK2", "JAK inhibitor lupus"
• Organ manifestation: Filter to nephritis-specific trials vs. broader SLE trials
• Sponsor filter: Track industry programs (competitive landscape) or include academic investigator-initiated studies
• Phase filter: Phase 1 for early pipeline intelligence, Phase 2/3 for near-term competitive threats

The CAR-T revolution in autoimmune disease

Perhaps no development has reshaped the SLE trial landscape more than the application of CAR-T cell therapy to autoimmune disease. Early data from European academic centers (notably Erlangen) showed durable remission in refractory SLE after anti-CD19 CAR-T — a result that has triggered a wave of commercial and academic programs.

The competitive dynamics are moving extremely fast:

• Multiple biotech companies have launched SLE CAR-T programs following the academic proof-of-concept
• The target landscape is expanding: CD19, CD20, BCMA, and combinations being explored
• Manufacturing improvements (in vivo CAR-T, allogeneic approaches) are entering trials to address cost and access
• Regulatory agencies have signaled strong interest in accelerated pathways for truly refractory SLE

Missing a competitor's CAR-T program registration is not an option for any serious lupus BD or investment team.

Who uses lupus trial monitoring

• Immunology-focused biotech BD teams — tracking competitor programs in SLE, LN, and related autoimmune conditions
• Pharma pipeline analysts — monitoring approved drug combinator trials and label extension studies
• Rheumatology-focused CROs — identifying enrollment competition for active SLE/LN studies
• Lupus patient advocacy organizations — staying current on clinical trial options for patients
• Healthcare investors — tracking lupus pipeline milestones for portfolio companies

Pricing

Basic — $49/month: 3 disease/keyword profiles, daily digest, ClinicalTrials.gov monitoring.

Professional — $149/month: Unlimited profiles, phase and sponsor filters, digest frequency options.

Team — $299/month: Everything in Professional for up to 5 users.

All plans include a 14-day free trial. Not charged until day 15.